Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL782P is a pseudogene derived from the 7SL RNA gene family, specifically classified as “RNA, 7SL, cytoplasmic 782, pseudogene”[1][4]. The parent 7SL RNA encodes the RNA component of the signal recognition particle (SRP), which plays an essential role in targeting secretory and membrane proteins to the endoplasmic reticulum in eukaryotes[3][5]. However, RN7SL782P is not a protein-coding gene and is not known to be expressed as a functional RNA[1][4][6]. Pseudogenes like RN7SL782P are typically regarded as genomic fossils, often produced by retrotransposition events; they generally lose their ability to code for functional products due to truncation, mutation, or loss of regulatory sequences[4][6]. While some pseudogenes elsewhere in the genome have been shown to impact cellular processes via non-coding RNA mechanisms (e.g., acting as competitive endogenous RNAs, weak regulators, or miRNA decoys), there is no evidence that RN7SL782P itself functions in this capacity[2]. RN7SL782P is not considered a therapeutic target, is not involved in drug interactions, and is not used as a biomarker. Its main scientific relevance lies in illustrating the evolutionary history and genomic propagation of SRP RNA-derived sequences. Summary of problems/limitations: - This entry refers to a pseudogene that does not encode a functional product. - It is not a therapeutic target (such as a receptor, enzyme, or transporter). - No evidence suggests it has a disease association or is a drug target. - Many 7SL pseudogenes exist in the genome, most of which have no known biological function or medical relevance[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 782, pseudogene (RN7SL782P).